Cathie Wood’s ARK Invest continued to reshuffle its healthcare portfolio Monday across its ETFs, selling heavily in Twist Bioscience Corp (NASDAQ:TWST) while directing fresh capital toward biotechnology and precision-medicine names.
Across its ARK Innovation ETF (BATS:ARKG) and ARK Genomic Revolution ETF (BATS:ARKK), ARK bought roughly $15 million of healthcare stocks while selling about $22 million. The biggest move was an approximately $18 million reduction in Twist, while purchases centered on Recursion Pharmaceuticals Inc (NASDAQ:RXRX), Veracyte Inc (NASDAQ:VCYT) and Intellia Therapeutics Inc (NASDAQ:NTLA).
The trades suggest ARK remains committed to genomics but is rotating exposure toward companies with clinical, diagnostic and drug-discovery catalysts.
ARKK Leans into Recursion and Intellia
Recursion received the largest combined purchase, at roughly $6.6 million, with about $5.3 million bought through ARKK and $1.3 million through ARKG.
ARK also bought approximately $1.2 million of Intellia, split between ARKK and ARKG. The purchase extended ARK’s Intellia buying streak to 50 consecutive sessions.
Intellia’s persistent accumulation is notable as the company approaches a major regulatory catalyst. The FDA has accepted its biologics application for lonvoguran ziclumeran, an investigational in-vivo CRISPR therapy for hereditary angioedema, for Priority Review. The drug has a March 10, 2027 PDUFA date. If approved, Intellia says the therapy could become the first in-vivo CRISPR-based treatment to reach the market.
ARKG Targets Precision Diagnostics
ARKG accounted for most of Monday’s other purchases.
The fund bought roughly $5.4 million of Veracyte, while also adding about $777,000 of Freenome, Inc (NASDAQ:FRNM) and $727,000 of Scribe Therapeutics Inc (NASDAQ:SCTX).
Veracyte’s recent operating momentum provides context for the purchase. The diagnostics company reported 15% year-over-year revenue growth to $150.3 million in the second quarter, with testing revenue rising 19%. It also acquired Convergent Genomics in September to expand its urinary cancer-testing capabilities.
Twist Selling Continues
On the other side of the ledger, ARK sold approximately $18 million of Twist, with roughly $9.5 million coming from ARKK and $8.5 million from ARKG.
The reduction marked the 21st consecutive session of Twist selling. ARKG also sold approximately $2.6 million of 10X Genomics Inc (NASDAQ:TXG) and $1.5 million of CareDx Inc (NASDAQ:CDNA).
Twist’s continued trimming is notable given the company’s exposure to AI-enabled drug discovery. It recently joined Eli Lilly And Co’s (NYSE:LLY) TuneLab, providing antibody characterization data for AI and machine-learning models aimed at accelerating drug discovery.
The Bigger ARK Signal
Monday’s trades look less like a retreat from biotech and more like rotation within the genomics theme.
ARKK’s buying was concentrated in Recursion and Intellia, while ARKG focused heavily on Veracyte and other precision-diagnostics names. Meanwhile, Twist accounted for roughly 80% of ARK’s combined healthcare selling that day.
The pattern fits a broader pharmaceutical industry shift toward AI-driven drug discovery, precision diagnostics and gene-editing platforms. For ARK, the emerging question is no longer simply whether genomics will transform healthcare, but which companies can convert those technologies into commercially viable medicines and diagnostics.
Photo: ARK Invest
